Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636
This examiner grants 40% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17630875 | SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 17544527 | Screening for Inhibitors of Prostaglandin E Synthase 3 Useful for Treatment of Prostate Cancer | Final Rejection | The Regents of the University of California |
| 17049320 | SPIKED PRIMERS FOR ENRICHMENT OF PATHOGEN NUCLEIC ACIDS AMONG BACKGROUND OF NUCLEIC ACIDS | Non-Final OA | The Regents of the University of California |
| 17085937 | BACTERIAL DEFENSE SYSTEMS AND METHODS OF IDENTIFYING THEREOF | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 19056045 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONS | Final Rejection | ACRIGEN BIOSCIENCES |
| 17403317 | METHOD FOR PRODUCING MODIFIED OLIGONUCLEOTIDE COMPRISING COMPLEMENTARY PORTION | Non-Final OA | Ajinomoto Co., Inc. |
| 18417305 | SYNTHETIC YEAST CELLS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18005311 | Targeted RNA cleavage with dCas13-RNase Fusion Proteins | Non-Final OA | University of Rochester |
| 17753659 | Highly Efficient DNA Base Editors Mediated By RNA-Aptamer Recruitment For Targeted Genome Modification And Uses Thereof | Final Rejection | Rutgers,The State University of New Jersey |
| 16991607 | EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN A BACTERIAL CELL-FREE SYNTHESIS SYSTEM USING BACTERIAL CELLS TRANSFORMED TO EXHIBIT ELEVATED LEVELS OF CHAPERONE EXPRESSION | Non-Final OA | Sutro Biopharma, Inc. |
| 18394091 | ANTIGEN-BINDING MOLECULE AND COMBINATION | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17611949 | MASS PRODUCTION SYSTEM OF RECOMBINANT BAGWORM SILK THREAD PROTEIN | Final Rejection | KOWA COMPANY, LTD. |
| 18012094 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | Non-Final OA | ModernaTX, Inc. |
| 18435438 | ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES | Final Rejection | Bruker Spatial Biology, Inc. |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | Non-Final OA | CureVac SE |
| 16093334 | GRNA FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | Final Rejection | Editas Medicine, Inc. |
| 18166868 | CURE ALL FOR NUCLEIC ACID-GUIDED CELL EDITING IN E. COLI | Non-Final OA | Inscripta, Inc. |
| 18005016 | FORMATE-INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | Non-Final OA | Imperial College Innovations Ltd |
| 17641426 | COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 | Non-Final OA | Scribe Therapeutics Inc. |
| 18042193 | A METHOD FOR THE ISOLATION OF DOUBLE-STRAND BREAKS | Non-Final OA | University College Cardiff Consultants Ltd |
| 17972463 | AUTOINDUCER-2 (AI-2) MOLECULAR RESPONSE-BASED STARTING ELEMENT AND ESCHERICHIA COLI (E. COLI) DYNAMIC REGULATION SYSTEM AND METHOD CONSTRUCTED THEREBY | Non-Final OA | BRIGHT DAIRY & FOOD CO., LTD |
| 16757289 | NOVEL ARTIFICIAL NUCLEIC ACID MOLECULES | Final Rejection | CureVac AG |
| 17615513 | IMPROVED METHODS AND COMPOSITIONS FOR INCREASED DOUBLE STRANDED RNA PRODUCTION | Non-Final OA | RNAISSANCE AG LLC |
| 17442057 | MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS | Non-Final OA | Encoded Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy